|
Founder’s Profile -
Dr. Mike Flanagan,
Co-Founder and CTO, Delve Therapeutics -
Delve Therapeutics is an early-stage biotech startup researching engineered cell therapies to treat metastatic cancers with a focus on pancreatic cancer. The team is currently working to expand the eligible patient population of TCR-T and TCR-NK therapies by making them patient HLA type agnostic.
Mike's path to biotechnology is unusual given that he started his career as a Rocket Scientist!! His early career was at NASA's Jet Propulsion Laboratory where he worked on Deep Space Network projects including the Search for ExtraTerrestrial Intelligence (SETI), followed by over a decade at Bell Laboratories. Mike received his undergraduate degree from Stevens Institute of Technology and his graduate degrees from the California Institute of Technology, including a PhD in Electrical Engineering.
Not surprisingly, Mike's previous entrepreneurial experience was in the tech sector, where he had been granted sixteen patents. He was the Chief Technology Officer at Arieso Ltd. Located in Newbury, UK, Arieso was a geo-location mobility solutions provider designing highly-accurate mobile network performance monitoring and optimization systems. JDSU acquired Arieso in 2013 for $85M.
Mike stayed with JDSU for a short time before pursuing interests in biotech and, in particular, synthetic biology. Projects relating to biomaterials, optogenetic control systems, bacterial photography and iGEM preceded his co-founding of Delve Therapeutics. Delve is currently located in the Incubator at North Brunswick.
Interesting side note about Mike - his son, Matt, played professionally for the Washington Commanders! After retiring from football, Matt supplemented his Rutgers Biology degree by earning his MBA from the University of Pittsburgh.
http://www.delvetx.com/
| 
